List of Excipients in Branded Drug RIFADIN IV

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sanofi-Aventis US LLC	RIFADIN IV	rifampin	0068-0597	SODIUM FORMALDEHYDE SULFOXYLATE
Sanofi-Aventis US LLC	RIFADIN IV	rifampin	0068-0597	SODIUM HYDROXIDE
Sanofi-Aventis US LLC	RIFADIN IV NOVAPLUS	rifampin	0068-0599	SODIUM FORMALDEHYDE SULFOXYLATE
Sanofi-Aventis US LLC	RIFADIN IV NOVAPLUS	rifampin	0068-0599	SODIUM HYDROXIDE

RIFADIN IV Excipient Strategy, Formulation Opportunities, and Commercial Outlook

Last updated: September 25, 2026

RIFADIN IV is an intravenous rifampin product supplied as a sterile lyophilized powder for reconstitution and infusion. Its commercial vulnerability is linked less to the rifampin molecule than to formulation complexity: aqueous instability, oxidation sensitivity, infusion compatibility, preparation time, discoloration, and hospital handling requirements. The strongest opportunities are ready-to-use presentations, improved stability, lower-risk excipient systems, and differentiated delivery formats for tuberculosis, staphylococcal infections, and patients unable to take oral therapy.

What is RIFADIN IV and how is it administered?

RIFADIN IV contains rifampin for intravenous infusion when oral administration is not clinically appropriate. The product is supplied in a single-dose vial as a sterile lyophilized formulation. The vial must be reconstituted with sterile water and diluted into a compatible intravenous solution before administration.[1]

The formulation includes rifampin and a stabilizing excipient system based on sodium formaldehyde sulfoxylate, with pH adjustment used to support product stability. The product is not administered as a direct intravenous bolus. Its preparation requirements create opportunities for competing products with simpler handling and longer in-use stability.

RIFADIN IV formulation profile

Attribute	RIFADIN IV profile
Active ingredient	Rifampin
Dosage form	Sterile lyophilized powder
Route	Intravenous infusion
Primary use	Tuberculosis and selected serious bacterial infections
Reconstitution	Sterile water for injection
Further dilution	Compatible intravenous infusion solution
Key formulation issue	Rifampin stability and compatibility in aqueous systems
Excipient strategy	Stabilizer, pH control, and lyophilized cake protection
Commercial limitation	Preparation burden and limited ready-to-use convenience

Rifampin is poorly suited to a simple aqueous injectable product because of its limited solubility and chemical sensitivity. A development program must control oxidation, hydrolysis, precipitation, adsorption to container surfaces, and degradation during storage and infusion.

What excipients are used in RIFADIN IV?

The principal excipient strategy is a lyophilized rifampin formulation containing a reducing or stabilizing component, with pH controlled during manufacture and reconstitution.[1] Public product information identifies sodium formaldehyde sulfoxylate as a formulation component. The precise quantitative composition, manufacturing process parameters, and container-closure specifications are controlled by the product manufacturer and regulatory filing.

The excipient system performs several functions:

1. It limits oxidative degradation of rifampin.
2. It supports stability during lyophilization and storage.
3. It maintains an acceptable reconstituted solution.
4. It reduces the risk of visible particles and precipitation.
5. It supports a commercially practical shelf life.

The formulation does not rely on a conventional high-concentration aqueous solution. The lyophilized presentation reduces the time rifampin spends in an aqueous environment before administration.

Critical excipient functions

Formulation function	Relevant excipient strategy	Development risk
Oxidation control	Reducing agent or oxygen-management system	Impurity formation, color change
pH control	Buffer or alkalinizing agent	Precipitation and infusion compatibility
Cake formation	Bulking agent or lyophilization aid	Collapse, shrinkage, reconstitution time
Solubility improvement	Cosolvent, surfactant, complexing agent	Toxicity, hemolysis, regulatory burden
Container protection	Low-binding vial and stopper system	Adsorption and extractables
In-use stability	Antioxidant and oxygen-control strategy	Limited post-reconstitution shelf life

What excipient opportunities exist for a RIFADIN IV competitor?

The best commercial opportunity is not a minor excipient substitution. It is a lower-burden intravenous product that preserves rifampin exposure while reducing pharmacy preparation and administration risk.

Ready-to-use intravenous bags

A ready-to-use bag could eliminate vial reconstitution and reduce compounding errors. The main technical challenge is maintaining rifampin stability in a liquid formulation for the intended shelf life.

Development would require assessment of:

• Rifampin concentration and solubility
• Container and tubing adsorption
• Oxidative degradation
• Bag material compatibility
• Light sensitivity
• Precipitation after dilution
• Stability under refrigerated and room-temperature storage
• Stability during simulated infusion

A ready-to-use bag would have a stronger hospital value proposition than a conventional generic vial because it could reduce preparation time, pharmacy labor, and exposure to manipulation.

Improved lyophilized formulation

A lower-risk approach is to retain the vial-and-lyophilized-powder format while improving:

• Reconstitution time
• Cake appearance
• Reconstituted solution stability
• In-use hold time
• Compatibility with common infusion fluids
• Packaging and labeling
• Dose preparation workflow

This route would likely face fewer clinical and regulatory challenges than a new liquid formulation. It may also be easier to position as a substitutable generic or abbreviated application, depending on the reference product and jurisdiction.

Alternative antioxidant systems

A competitor could investigate alternatives to the incumbent stabilizer, including:

• Ascorbate-based systems
• Sulfite or bisulfite systems
• Thiol-based reducing agents
• Oxygen scavengers in the container
• Nitrogen purging
• Low-oxygen vial filling
• Chelating agents where metal-catalyzed oxidation is relevant

Each alternative introduces a new safety and compatibility profile. Sulfite systems may raise sensitivity concerns in susceptible patients. Thiol-containing excipients may create odor, impurity, or regulatory issues. Ascorbate systems may themselves undergo oxidative degradation and change solution color.

The strongest patent position would likely arise from a specific combination of rifampin concentration, stabilizer level, pH, lyophilization cycle, oxygen level, container closure, and demonstrated stability rather than from a generic claim to an antioxidant.

Cyclodextrin or solubilizer-enabled formulation

Cyclodextrins, surfactants, and cosolvents could improve apparent rifampin solubility. These systems carry a greater regulatory burden because parenteral exposure to the excipient can create renal, hemolytic, or local-tolerance concerns.

A solubilized formulation would need to demonstrate:

• No precipitation after dilution
• No clinically meaningful hemolysis
• Acceptable infusion-site tolerability
• Stable rifampin exposure
• No unacceptable interaction with infusion tubing
• No adverse impact on antimicrobial activity

This opportunity is technically attractive but less likely to be the fastest path to market than an improved lyophilized product.

What formulation patents could protect a RIFADIN IV competitor?

A modern rifampin IV patent strategy should focus on formulation and manufacturing claims because legacy composition-of-matter protection for rifampin is expired.

Potential claim categories include:

Claim category	Potential protected subject matter
Composition	Rifampin with a defined stabilizer, pH range, and excipient ratio
Lyophilized cake	Specific bulking agent, residual moisture, and reconstitution profile
Liquid formulation	Rifampin concentration, solubilizer, antioxidant, and pH
Container closure	Low-oxygen vial, stopper, bag, or oxygen-scavenging package
Infusion system	Premixed bag, tubing set, or administration configuration
Stability	Defined impurity limit after storage or infusion
Manufacturing	Nitrogen purge, lyophilization cycle, aseptic filling, or order of addition
Use	Intravenous rifampin dosing in patients unable to receive oral therapy

The most defensible patents would combine composition and performance limitations. A claim directed only to rifampin plus a known antioxidant would face substantial prior-art risk. A claim requiring a particular impurity profile, reconstitution time, storage period, or infusion compatibility result would be more difficult to design around if the data are strong.

When does RIFADIN IV lose exclusivity?

Rifampin's active ingredient and early product patents are long expired. Any remaining commercial protection would be expected to arise from formulation, manufacturing, regulatory exclusivity, trademark rights, or jurisdiction-specific product listings rather than from the rifampin molecule itself.

Patent and regulatory exclusivity

Protection type	Strategic position
Rifampin composition of matter	Expired
Original injectable formulation patents	Expected to be expired or commercially weak
Current formulation patents	Must be confirmed through jurisdiction-specific searches
FDA orphan exclusivity	Not generally associated with standard RIFADIN IV use
Pediatric exclusivity	No product-specific conclusion without current FDA records
Orange Book patents	Must be checked against the current FDA listing
Trademark	RIFADIN brand rights may remain separate from patent rights
Manufacturing know-how	Potentially relevant if process complexity limits entry

A generic applicant would typically evaluate the FDA Orange Book, Drugs@FDA records, public labeling, and any listed patents associated with the reference product.[2,3] A Paragraph IV certification would be relevant only if an unexpired patent were listed against the reference product. For an old rifampin injection, the principal risk is more likely technical equivalence and commercial supply than a fundamental molecule patent.

What is the Orange Book status of RIFADIN IV?

The Orange Book status must be evaluated using the current product listing, application number, marketing status, and patent data. Historical FDA approval or label availability does not by itself establish current commercial marketing.

For an ANDA strategy, the relevant questions are:

• Whether RIFADIN IV remains listed as the reference listed drug
• Whether the reference product is currently marketed
• Whether a suitable reference standard is available
• Whether any patents or exclusivities remain listed
• Whether the product has been discontinued or withdrawn for reasons other than safety or effectiveness
• Whether the proposed product can demonstrate pharmaceutical equivalence and bioequivalence or qualify for an alternative pathway

If no unexpired listed patent remains, a Paragraph IV challenge may have limited relevance. A first-filer opportunity would also depend on whether any qualifying patent certification and exclusivity framework remains active.

Which companies are challenging RIFADIN IV?

No reliable current public record establishes a major active Paragraph IV litigation campaign against RIFADIN IV. The product is an older injectable antibiotic, and the competitive field is more likely to consist of generic manufacturers, hospital suppliers, and contract manufacturers than branded patent challengers.

Potential competitors include manufacturers offering rifampin for injection under generic names or regional brands. The relevant competitive screen should cover the United States, Europe, India, China, Canada, and hospital markets in tuberculosis-endemic countries.

A commercial diligence review should identify:

• Current product registrations
• Active national marketing authorizations
• Manufacturing sites
• Drug-shortage records
• Hospital-contract participation
• Approved vial sizes
• Stability claims
• Ready-to-use or premixed presentations
• Government procurement awards

What regulatory pathway applies to a new RIFADIN IV product?

A conventional generic vial may qualify for an abbreviated pathway if the applicant can establish pharmaceutical equivalence, bioequivalence where required, and comparable quality attributes. An injectable product may face a more complex assessment when differences in excipients, concentration, formulation state, or administration instructions affect equivalence.

A materially reformulated ready-to-use product could require a more extensive 505(b)(2)-type strategy in the United States, depending on the formulation and reliance on the listed drug. The regulatory burden increases if the product changes:

• Route or infusion method
• Concentration
• Diluent
• Administration duration
• Excipient exposure
• Stability after preparation
• Container system
• Patient population

FDA injectable guidance emphasizes control of sterility, particulate matter, extractables and leachables, container closure, endotoxins, and product-specific stability.[4] Rifampin products also require careful evaluation of discoloration and degradation products because visual changes can affect hospital acceptance and release testing.

How strong is the patent estate for a new RIFADIN IV formulation?

The legacy patent estate is likely weak as a barrier to a technically capable generic manufacturer. The stronger intellectual-property opportunity is a new formulation platform with demonstrated clinical or operational value.

High-value patent targets

A new entrant should prioritize patents covering:

1. A stable liquid rifampin formulation suitable for storage and infusion.
2. A lyophilized composition with rapid reconstitution.
3. A low-oxygen container-closure system.
4. A premixed infusion bag with defined in-use stability.
5. A specific impurity profile after storage and administration.
6. A manufacturing sequence that prevents precipitation or degradation.
7. A formulation compatible with common infusion fluids and tubing.

Trade secrets may be as important as patents. The most difficult manufacturing elements may include oxygen control, lyophilization cycle design, stopper selection, filling temperature, order of excipient addition, and control of residual moisture.

What commercial opportunities exist for RIFADIN IV excipients?

The commercial opportunity is concentrated in hospital-use convenience and supply reliability.

Opportunity	Customer value	Development priority
Improved lyophilized vial	Lower preparation burden	High
Ready-to-use bag	Eliminates reconstitution	High but technically difficult
Longer post-reconstitution stability	Reduces waste	High
Compatible premix with standard diluents	Simplifies pharmacy workflow	High
Lower-cost stabilizer system	Improves margin	Medium
Low-adsorption packaging	Supports dose consistency	Medium
Pediatric or weight-based presentation	Reduces dose manipulation	Medium
Dual-chamber system	Separates unstable components until use	Medium to high

The most attractive product is a ready-to-administer or dual-chamber presentation with a clinically justified storage period. A lower-cost vial may capture volume, but it will compete primarily on price. A ready-to-use product can compete on labor savings, error reduction, and supply-chain simplicity.

What revenue exposure does RIFADIN IV represent?

Public company disclosures generally do not report RIFADIN IV revenue as a separate line item. The product should therefore be modeled using market data rather than brand-level financial statements.

Revenue potential depends on:

• Intravenous rifampin unit demand
• Hospital procurement pricing
• Tuberculosis program purchases
• Shortage-driven price increases
• Generic competition
• Product availability by geography
• Cost of goods for sterile manufacturing
• Waste from short in-use stability
• Premium for premixed delivery

The addressable market is narrower than the total rifampin market because oral rifampin remains the dominant route. Intravenous demand is concentrated in severe infection, critical care, perioperative use, and patients unable to absorb or tolerate oral therapy.

What generic launch scenarios exist for RIFADIN IV?

Scenario 1: Low-cost generic lyophilized vial

This is the fastest and lowest-risk commercial route. It requires competitive sterile manufacturing and reliable supply but offers limited differentiation. Price erosion could be substantial if multiple suppliers enter.

Scenario 2: Improved lyophilized vial

A product with faster reconstitution, better stability, or fewer preparation steps could secure hospital formulary preference without requiring a major clinical development program.

Scenario 3: Ready-to-use infusion bag

This has the strongest differentiation but requires more extensive stability, packaging, compatibility, and regulatory work. It may command a premium if it reduces pharmacy labor and medication-preparation risk.

Scenario 4: Dual-chamber container

A dual-chamber vial or bag could preserve rifampin in a dry state until administration. This approach may offer a compromise between stability and convenience, but device development and combination-product requirements increase the execution burden.

Key Takeaways

• RIFADIN IV relies on a lyophilized rifampin formulation because aqueous stability and solubility create technical constraints.
• Sodium formaldehyde sulfoxylate and pH control are central elements of the historical formulation strategy.
• The strongest commercial opportunity is an improved lyophilized vial, ready-to-use bag, or dual-chamber product.
• Rifampin molecule patents are expired; meaningful new protection would need to cover formulation, packaging, stability, manufacturing, or administration.
• A Paragraph IV strategy has limited value unless current Orange Book records identify an unexpired listed patent.
• The main barriers are sterile manufacturing, stability, precipitation control, container compatibility, and regulatory equivalence.
• Hospital convenience and supply reliability are more promising sources of product differentiation than a basic excipient substitution.
• Product-level RIFADIN IV revenue is not generally disclosed, so investment analysis should use unit demand, procurement pricing, and hospital-use data.

FAQs About RIFADIN IV Excipient and Patent Opportunities

Can rifampin injection be converted from a lyophilized vial to a liquid formulation?

Yes, but the liquid product must control solubility, oxidation, precipitation, container adsorption, and infusion compatibility over its proposed shelf life. The regulatory burden would generally exceed that of an improved lyophilized formulation.

Which excipient is most important for rifampin injectable stability?

The reducing or antioxidant system is central, but stability also depends on pH, dissolved oxygen, residual moisture, container closure, and the lyophilization cycle. No single excipient determines product performance.

Does a new rifampin IV formulation need new clinical trials?

Not necessarily. A pharmaceutically equivalent generic may rely on an abbreviated pathway. A materially different liquid, premixed, or device-enabled product may require additional studies under the applicable regulatory pathway.

Can a company patent a new rifampin infusion bag?

Yes. Patentable subject matter could include the rifampin concentration, stabilizer system, bag material, oxygen-control method, storage period, infusion compatibility, or manufacturing process. Patentability depends on novelty, nonobviousness, enablement, and the prior art.

Is a ready-to-use rifampin IV product commercially attractive?

Yes, if it demonstrates meaningful stability and reduces pharmacy preparation. Its market potential is limited by the size of the intravenous rifampin segment, but hospitals may pay a premium for lower handling burden and improved supply reliability.

References

1. Sanofi-Aventis U.S. LLC. (n.d.). RIFADIN IV (rifampin for injection) prescribing information. U.S. Food and Drug Administration labeling repository.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2014). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice. https://www.fda.gov/regulatory-information/search-fda-guidance-documents